Researchers assessed clinical features, muscle biopsy scores, and myositis-specific antibody profiles in juvenile dermatomyositis, and their association with disease outcomes and treatment responses in patients.
Researchers aimed to evaluate the feasibility of studying creatine in juvenile dermatomyositis and to determine the effect of creatine on muscle function and metabolism.
The study authors’ goal was to raise the possibility that some patients with polymyalgia rheumatica and type 2 diabetes mellitus can avoid glucocorticoid treatment.
Researchers investigated the content validity of patient-reported outcome measures in patients with idiopathic inflammatory myopathies.
Experts highlight the need for cancer screening strategies in patients with rheumatic diseases.
A triple steroid/intravenous immunoglobulin/steroid-sparing immunosuppressant induction strategy was effective for the treatment of statin-induced anti-HMGCR myopathy.
Muscle disease is more prominent among patients with dermatomyositis and anti-Mi2 autoantibodies compared with in those who have anti-Mi2-negative dermatomyositis.
A clinical expert panel from the Sjögren’s Syndrome Foundation has published the first-ever clinical practice guidelines for the disease in the United States.
Five randomized controlled trials including adult patients with polymyositis and dermatomyositis (DM) and additional open studies have demonstrated reduced impairment and activity limitation as well as improved quality of life. Exercise can improve muscle aerobic capacity as shown by increased mitochondrial enzyme activity. These data suggest that intensive aerobic exercise and resistance training could reduce disease activity and inflammation and improve muscle metabolism.
